当前位置: 首页 >> 检索结果
961. A novel unconventional T cell population enriched in Crohn's disease.
作者: Elisa Rosati.;Gabriela Rios Martini.;Mikhail V Pogorelyy.;Anastasia A Minervina.;Frauke Degenhardt.;Mareike Wendorff.;Soner Sari.;Gabriele Mayr.;Antonella Fazio.;Christel Marie Dowds.;Charlotte Hauser.;Florian Tran.;Witigo von Schönfels.;Julius Pochhammer.;Maria A Salnikova.;Charlot Jaeckel.;Johannes Boy Gigla.;Sanaz Sedghpour Sabet.;Matthias Hübenthal.;Esther Schiminsky.;Stefan Schreiber.;Philip C Rosenstiel.;Alexander Scheffold.;Paul G Thomas.;Wolfgang Lieb.;Bernd Bokemeyer.;Maria Witte.;Konrad Aden.;Alexander Hendricks.;Clemens Schafmayer.;Jan-Hendrick Egberts.;Ilgar Z Mamedov.;Petra Bacher.;Andre Franke.
来源: Gut. 2022年71卷11期2194-2204页
One of the current hypotheses to explain the proinflammatory immune response in IBD is a dysregulated T cell reaction to yet unknown intestinal antigens. As such, it may be possible to identify disease-associated T cell clonotypes by analysing the peripheral and intestinal T-cell receptor (TCR) repertoire of patients with IBD and controls.
963. A faecal microbiota signature with high specificity for pancreatic cancer.
作者: Ece Kartal.;Thomas S B Schmidt.;Esther Molina-Montes.;Sandra Rodríguez-Perales.;Jakob Wirbel.;Oleksandr M Maistrenko.;Wasiu A Akanni.;Bilal Alashkar Alhamwe.;Renato J Alves.;Alfredo Carrato.;Hans-Peter Erasmus.;Lidia Estudillo.;Fabian Finkelmeier.;Anthony Fullam.;Anna M Glazek.;Paulina Gómez-Rubio.;Rajna Hercog.;Ferris Jung.;Stefanie Kandels.;Stephan Kersting.;Melanie Langheinrich.;Mirari Márquez.;Xavier Molero.;Askarbek Orakov.;Thea Van Rossum.;Raul Torres-Ruiz.;Anja Telzerow.;Konrad Zych.; .; .;Vladimir Benes.;Georg Zeller.;Jonel Trebicka.;Francisco X Real.;Nuria Malats.;Peer Bork.
来源: Gut. 2022年71卷7期1359-1372页
Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression.
966. Oncological outcomes after piecemeal endoscopic mucosal resection of large non-pedunculated colorectal polyps with covert submucosal invasive cancer.
作者: Dave J Gibson.;Mayenaaz Sidhu.;Simon Zanati.;David J Tate.;Dileep Mangira.;Alan Moss.;Rajvinder Singh.;Luke F Hourigan.;Spiro Raftopoulos.;Alan Pham.;Phil Kostos.;M Priyanthi Kumarasinghe.;Andrew Ruszkiewicz.;Duncan McLeod.;Gregor J E Brown.;Michael J Bourke.
来源: Gut. 2022年71卷12期2481-2488页
Management of covert submucosal invasive cancer (SMIC) discovered after piecemeal endoscopic mucosal resection (pEMR) of large (>20 mm) non-pedunculated colorectal polyps is challenging. The residual cancer risk is largely unknown. We sought to evaluate this in a large tertiary referral cohort.
968. Epithelial RAC1-dependent cytoskeleton dynamics controls cell mechanics, cell shedding and barrier integrity in intestinal inflammation.
作者: Luz Del Carmen Martínez-Sánchez.;Phuong Anh Ngo.;Rashmita Pradhan.;Lukas-Sebastian Becker.;David Boehringer.;Despina Soteriou.;Marketa Kubankova.;Christine Schweitzer.;Tatyana Koch.;Veronika Thonn.;Lena Erkert.;Iris Stolzer.;Claudia Günther.;Christoph Becker.;Benno Weigmann.;Monika Klewer.;Christoph Daniel.;Kerstin Amann.;Stefan Tenzer.;Raja Atreya.;Martin Bergo.;Cord Brakebusch.;Alastair J M Watson.;Jochen Guck.;Ben Fabry.;Imke Atreya.;Markus F Neurath.;Rocío López-Posadas.
来源: Gut. 2023年72卷2期275-294页
Increased apoptotic shedding has been linked to intestinal barrier dysfunction and development of inflammatory bowel diseases (IBD). In contrast, physiological cell shedding allows the renewal of the epithelial monolayer without compromising the barrier function. Here, we investigated the role of live cell extrusion in epithelial barrier alterations in IBD.
969. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis.
作者: Chuangen Li.;Yong Wang.;Dabin Liu.;Chi Chun Wong.;Olabisi Oluwabukola Coker.;Xiang Zhang.;Changan Liu.;Yunfei Zhou.;Yali Liu.;Wei Kang.;Ka Fai To.;Joseph Jy Sung.;Jun Yu.
来源: Gut. 2022年71卷11期2253-2265页
Aberrant lipid metabolism is a hallmark of colorectal cancer (CRC). Squalene epoxidase (SQLE), a rate-limiting enzyme in cholesterol biosynthesis, is upregulated in CRC. Here, we aim to determine oncogenic function of SQLE and its interplay with gut microbiota in promoting colorectal tumourigenesis.
971. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
作者: Carla Montironi.;Florian Castet.;Philipp K Haber.;Roser Pinyol.;Miguel Torres-Martin.;Laura Torrens.;Agavni Mesropian.;Huan Wang.;Marc Puigvehi.;Miho Maeda.;Wei Qiang Leow.;Elizabeth Harrod.;Patricia Taik.;Jigjidsuren Chinburen.;Erdenebileg Taivanbaatar.;Enkhbold Chinbold.;Manel Solé Arqués.;Michael Donovan.;Swan Thung.;Jaclyn Neely.;Vincenzo Mazzaferro.;Jeffrey Anderson.;Sasan Roayaie.;Myron Schwartz.;Augusto Villanueva.;Scott L Friedman.;Andrew Uzilov.;Daniela Sia.;Josep M Llovet.
来源: Gut. 2023年72卷1期129-140页
We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy.
974. Real-life multicentre study of lumen-apposing metal stent for EUS-guided drainage of pancreatic fluid collections.
作者: Arnaldo Amato.;Ilaria Tarantino.;Antonio Facciorusso.;Cecilia Binda.;Stefano Francesco Crinò.;Alessandro Fugazza.;Edoardo Forti.;Maria Chiara Petrone.;Roberto Di Mitri.;Raffaele Macchiarelli.;Emanuele Sinagra.;Marcello Maida.;Alessandro Repici.;Andrea Anderloni.;Carlo Fabbri.; .
来源: Gut. 2022年71卷6期1050-1052页 975. Cultivated human intestinal fungus Candida metapsilosis M2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists.
作者: Xiaokui Huo.;Dawei Li.;Fan Wu.;Shenghui Li.;Yanling Qiao.;Chao Wang.;Yan Wang.;Changjiang Zhou.;Liqun Sun.;Zhilin Luan.;Qiulong Yan.;Jiayue Wang.;Yu Zhang.;Ting Zhao.;Yue An.;Baojing Zhang.;Xiangge Tian.;Zhenlong Yu.;Xiaochi Ma.
来源: Gut. 2022年71卷11期2205-2217页
Dysbiosis of the intestinal fungal community has been observed in inflammatory bowel disease (IBD); however, its potential role in IBD development and prevention remains unclear. Here, we explored the biological effects and molecular mechanisms of intestinal fungi isolated from human faeces on colitis in mice.
976. PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.
作者: Xianyong Gui.;Alina Bazarova.;Rocìo Del Amor.;Michael Vieth.;Gert de Hertogh.;Vincenzo Villanacci.;Davide Zardo.;Tommaso Lorenzo Parigi.;Elin Synnøve Røyset.;Uday N Shivaji.;Melissa Anna Teresa Monica.;Giulio Mandelli.;Pradeep Bhandari.;Silvio Danese.;Jose G Ferraz.;Bu'Hussain Hayee.;Mark Lazarev.;Adolfo Parra-Blanco.;Luca Pastorelli.;Remo Panaccione.;Timo Rath.;Gian Eugenio Tontini.;Ralf Kiesslich.;Raf Bisschops.;Enrico Grisan.;Valery Naranjo.;Subrata Ghosh.;Marietta Iacucci.
来源: Gut. 2022年71卷5期889-898页
Histological remission is evolving as an important treatment target in UC. We aimed to develop a simple histological index, aligned to endoscopy, correlated with clinical outcomes, and suited to apply to an artificial intelligence (AI) system to evaluate inflammatory activity.
977. PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.
作者: Li-Gong Lu.;Zhi-Ling Zhou.;Xu-Yan Wang.;Bo-Yuan Liu.;Jin-Ying Lu.;Shuai Liu.;Guang-Bo Zhang.;Mei-Xiao Zhan.;Yun Chen.
来源: Gut. 2022年71卷12期2551-2560页
Patients with increased PD-L1+ host cells in tumours are more potent to benefit from antiprogrammed death-1/programmed death ligand-1 (PD-L1) treatment, but the underlying mechanism is still unclear. We aim to elucidate the nature, regulation and functional relevance of PD-L1+ host cells in hepatocellular carcinoma (HCC).
979. Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial.
作者: Christina M Brennan.;Sandeep Nadella.;Xiang Zhao.;Richard J Dima.;Nicole Jordan-Martin.;Breanna R Demestichas.;Sam O Kleeman.;Miriam Ferrer.;Eva Carlotta von Gablenz.;Nicholas Mourikis.;Michael E Rubin.;Harsha Adnani.;Hassal Lee.;Taehoon Ha.;Soma Prum.;Cheryl B Schleicher.;Sharon S Fox.;Michael G Ryan.;Christina Pili.;Gary Goldberg.;James M Crawford.;Sara Goodwin.;Xiaoyue Zhang.;Jonathan B Preall.;Ana S H Costa.;Joseph Conigliaro.;Joseph R Masci.;Jie Yang.;David A Tuveson.;Kevin J Tracey.;Tobias Janowitz.
来源: Gut. 2022年71卷5期879-888页
We assessed whether famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-19.
980. EUS versus MRCP to perform ERCP in patients with intermediate likelihood of choledocholithiasis: a randomised controlled trial.
作者: Nitin Jagtap.;J Kiran Kumar.;Radhika Chavan.;Jahangeer Basha.;Manu Tandan.;Sundeep Lakhtakia.;Rakesh Kalapala.;Zaheer Nabi.;Rajesh Gupta.;Mohan Ramchandani.;Rupjyoti Talukdar.;Manohar Reddy.;Raghavendra Yarlagadda.;Jagadish Singh.;Sana Fatima Memon.;G Venkat Rao.;D Nageshwar Reddy.
来源: Gut. 2022年
In patients with an intermediate likelihood of choledocholithiasis, European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend endoscopic ultrasound (EUS) or magnetic resonance cholangiopancreatography (MRCP) to diagnose choledocholithiasis to make the indication for endoscopic retrograde cholangiopancreatography (ERCP) treatment; there is no randomised control trial to compare both in this setting.
|